Here’s When Pfizer’s CEO Says the Company Might Get Back to Generating High-Single-Digit Growth

Pfizer’s stock performance has struggled, with sales declining last year and limited investor enthusiasm despite its notably high dividend yield of 6.6%, which surpasses the S&P 500 average of 1.1%. However, company leadership anticipates a positive shift in growth in the near future.

Optimistic Growth Projections Starting in 2029

During the first-quarter earnings call, Pfizer CEO Albert Bourla expressed optimism that beginning in 2029, the company would enter a five-year period marked by robust revenue growth in the high single digits. A significant factor contributing to this outlook is a recent settlement extending the patent protections for Pfizer’s Vyndamax drug until 2031.

This extension modifies previous expectations of a sharp revenue drop starting in 2029, now forecasting stable sales of Vyndamax from 2028 through mid-2031.

Investments in Healthcare Portfolio and Research

Pfizer is actively investing in expanding its healthcare portfolio, with plans to initiate 20 pivotal studies within the year. The company also expects decisions on four regulatory approvals, highlighting 2026 as a crucial year for research and development efforts.

These investments aim to foster future growth and strengthen Pfizer’s market position.

Stock Performance and Investment Considerations

Although Pfizer’s stock has declined over 30% in the past five years and is not currently listed among top stock picks for immediate buying, the company’s strategic initiatives and valuation—trading at approximately nine times projected future earnings—may appeal to patient, long-term investors seeking potential returns combined with a strong dividend yield.

Investors should consider the timeline for growth recovery and maintain a long-term perspective, as the anticipated improvement is several years away. Nonetheless, Pfizer’s ongoing research and development and extended patent protections lay a foundation for renewed growth prospects starting at the end of this decade.

Key Takeaways

  • Pfizer expects a return to high single-digit revenue growth starting in 2029, sustained for five years.
  • Patent protection for Vyndamax has been extended to 2031, stabilizing expected sales through mid-2031.
  • Significant investment in healthcare research is underway, with 20 pivotal studies and potential regulatory approvals expected.
  • The company’s stock has declined over 30% in five years but remains attractive to long-term investors due to strong dividends and valuation.
  • Growth recovery is anticipated several years ahead, requiring investor patience and a long-term outlook.